Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FERNANDO C TRESPALACIOS

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1710969688
CMS profile
33093
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$1,025.12

45 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,008.85 44
Education $16.27 1

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 1; records 1–45 of 45 matching records. This page contains 45 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FERNANDO C TRESPALACIOS

NPI 1710969688 · CMS profile ID 33093

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–45 of 45 matching records. This page contains 45 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1710969688?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FERNANDO C TRESPALACIOS, NPI 1710969688, CMS profile ID 33093. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–45 of 45 matching records. This page contains 45 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1710969688?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). FERNANDO C TRESPALACIOS, NPI 1710969688, CMS profile ID 33093. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–45 of 45 matching records. This page contains 45 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1710969688?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
FERNANDO C TRESPALACIOS, NPI 1710969688, CMS profile ID 33093, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–45 of 45 matching records. This page contains 45 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1710969688?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

45 matching records · $1,025.12 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 45 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–45 of 45.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Calliditas Therapeutics US Inc. $30.1812/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235009555 CMS
Bayer Healthcare Pharmaceuticals Inc. $17.2112/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225858457 CMS
Ardelyx, Inc. $22.7312/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247888975 CMS
Ardelyx, Inc. $22.4611/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247888973 CMS
AstraZeneca Pharmaceuticals LP $21.1911/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206859166 CMS
Calliditas Therapeutics US Inc. $18.8111/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235009553 CMS
AstraZeneca Pharmaceuticals LP $23.2410/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206591850 CMS
Novo Nordisk Inc $21.2810/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188898663 CMS
Travere Therapeutics, Inc. $26.8910/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244396852 CMS
AstraZeneca Pharmaceuticals LP $21.0910/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206668900 CMS
AstraZeneca Pharmaceuticals LP $23.2409/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207259943 CMS
Amgen Inc. $20.9509/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228381304 CMS
Novartis Pharmaceuticals Corporation $29.7309/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200554011 CMS
Otsuka America Pharmaceutical, Inc. $24.0808/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227520749 CMS
AstraZeneca Pharmaceuticals LP $19.8108/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206429918 CMS
Amgen Inc. $24.3108/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228381302 CMS
AstraZeneca Pharmaceuticals LP $23.2208/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206932417 CMS
Fresenius USA Marketing, Inc. $14.3507/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244806297 CMS
AstraZeneca Pharmaceuticals LP $22.7107/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206860733 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.1807/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222847341 CMS
Fresenius USA Marketing, Inc. $19.8206/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244816737 CMS
AstraZeneca Pharmaceuticals LP $26.9406/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207186239 CMS
AstraZeneca Pharmaceuticals LP $20.8906/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206231030 CMS
AstraZeneca Pharmaceuticals LP $23.4405/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206506837 CMS
Mallinckrodt Hospital Products Inc. $33.9305/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212004515 CMS
Fresenius USA Marketing, Inc. $20.6505/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244806299 CMS
Amgen Inc. $22.4605/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228381300 CMS
SCPHARMACEUTICALS INC. $24.1805/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228185328 CMS
Novo Nordisk Inc $14.4004/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188510884 CMS
Novo Nordisk Inc $16.2704/23/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1188765707 CMS
Amgen Inc. $22.8204/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228381306 CMS
AstraZeneca Pharmaceuticals LP $24.8104/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206753414 CMS
Vifor Pharma, Inc. $27.9204/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1172033194 CMS
Ardelyx, Inc. $24.8003/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247888971 CMS
Ardelyx, Inc. $25.0003/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247888969 CMS
Travere Therapeutics, Inc. $23.8703/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244396848 CMS
Travere Therapeutics, Inc. $26.6103/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244396850 CMS
AstraZeneca Pharmaceuticals LP $20.5203/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206370487 CMS
Otsuka America Pharmaceutical, Inc. $28.0103/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227520745 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $24.4502/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222847339 CMS
AstraZeneca Pharmaceuticals LP $21.5802/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206833057 CMS
Calliditas Therapeutics US Inc. $19.9901/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235009551 CMS
AstraZeneca Pharmaceuticals LP $23.1501/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207171699 CMS
Calliditas Therapeutics US Inc. $16.5501/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235009549 CMS
AstraZeneca Pharmaceuticals LP $27.4001/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206554608 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $470.87 23
PY2020 $199.26 6
PY2021 $149.72 7
PY2022 $349.47 17
PY2023 $768.02 36
PY2024 $1,659.34 76
PY2025 $1,025.12 45

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $127,773.94 29
PY2024 Principal investigator $61,305.22 20
PY2023 Principal investigator $51,520.60 25
PY2022 Principal investigator $3,771.50 6
PY2021 Principal investigator $54,919.40 17
PY2020 Principal investigator $115,052.17 24
PY2019 Principal investigator $206,858.59 208

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

29 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 CSL Behring $2,218.00 12/29/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252675696
Principal investigator 1 CSL Behring $200.00 12/05/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252675872
Principal investigator 1 CSL Behring $2,454.00 12/05/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252675874
Principal investigator 1 CSL Behring $9,750.00 12/05/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252675876
Principal investigator 1 CSL Behring $3,240.00 11/17/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252676164
Principal investigator 1 CSL Behring $10,112.60 10/29/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252676070
Principal investigator 1 CSL Behring $700.51 10/09/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674584
Principal investigator 1 CSL Behring $4,680.00 09/17/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252676242
Principal investigator 1 CSL Behring $25.97 08/25/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674448
Principal investigator 1 CSL Behring $514.58 08/20/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674752
Principal investigator 1 CSL Behring $5,564.00 08/20/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252676484
Principal investigator 1 CSL Behring $16.71 08/04/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674836
Principal investigator 1 CSL Behring $9,474.00 07/16/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252676726
Principal investigator 1 CSL Behring $7,020.00 06/30/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252676916
Principal investigator 1 CSL Behring $500.00 05/28/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252677166
Principal investigator 1 CSL Behring $7,180.00 05/14/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252677046
Principal investigator 1 CSL Behring $243.21 05/07/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252675156
Principal investigator 1 CSL Behring $216.22 04/17/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252675078
Principal investigator 1 CSL Behring $5,564.00 04/16/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252677332
Principal investigator 1 CSL Behring $16.71 04/08/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252675390
Principal investigator 1 CSL Behring $423.76 03/27/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252675314
Principal investigator 1 CSL Behring $177.29 03/20/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252675260
Principal investigator 1 CSL Behring $7,904.00 03/19/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252677558
Principal investigator 1 CSL Behring $483.71 02/21/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252675632
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $26,167.77 02/21/2025 Non-covered Recipient Entity
NEPHROLOGY ASSOCIATES OF SOUTH MIAMI P.A.
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Povetacicept in Adults With Immunoglobulin A Nephropathy (RAINIER) No dispute reported 06/30/2026 1214125128
Principal investigator 1 CSL Behring $13,115.00 02/19/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252677462
Principal investigator 1 CSL Behring $131.90 02/05/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252675442
Principal investigator 1 CSL Behring $4,680.00 01/10/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252677712
Principal investigator 1 CSL Behring $5,000.00 01/10/2025 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252677714